Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Between 18-35 years of age~* 37 weeks gestation~* Breech presentation~Exclusion Criteria:~* Patients with ruptured membranes~* Multiple gestation~* Maternal age (age \> 35)~* With known medical comorbidities (including hypertension (HTN), arrhythmias, endocrinologic diseases such as diabetes and thyroid disease, scoliosis, asthma)~* Allergies to nitroglycerine or terbutaline~* Prior abdominal or uterine surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Intravenous Terbutaline (Type: ACTIVE_COMPARATOR): 0.25 mL of Intravenous Terbutaline
- Intravenous Nitroglycerine (Type: ACTIVE_COMPARATOR): IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.

Based on this trial design, predict the completion outcome and termination type (if applicable).